Biomarker & Intervention Discovery
Melanoma
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs430.5KWHO GHE 2021 · all ages
Global DALYs3.30MWHO GHE 2021 · worldwide
US mortality14.7K deaths/yrWHO GHE 2021
Global mortality131.9K deaths/yrWHO GHE 2021 · worldwide
NIH funding$285MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionSpontaneous regression documented in ~0.4% of metastatic melanoma cases; early-stage surgical resection: 90%+ 5-year…
Best-intervention remissionStage IV with PD-1/CTLA-4 combination (nivolumab + ipilimumab): 52% 5-year OS (CheckMate-067); BRAF V600E + MEK…
Gap sizeModerate — genuine cures are now achievable for many Stage IV melanoma patients; the question is maximising who can…
Primary barrieraccess
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous regression documented in ~0.4% of metastatic melanoma cases; early-stage surgical resection: 90%+ 5-year survival for Stage I; Stage IV (metastatic): historically <10% 5-year survival
Best-intervention remission
Stage IV with PD-1/CTLA-4 combination (nivolumab + ipilimumab): 52% 5-year OS (CheckMate-067); BRAF V600E + MEK inhibition (dabrafenib + trametinib): 34% 5-year OS; pembrolizumab adjuvant Stage III: 58.4% vs 45.9% RFS at 5 years; TIL therapy (Amtagvi): 31.5% ORR in heavily pretreated patients
Gap size
Moderate — genuine cures are now achievable for many Stage IV melanoma patients; the question is maximising who can access these outcomes
Immunotherapy combination (nivolumab + ipilimumab) achieves durable responses in ~25-30% of Stage IV patients (functional cure); BRAF-targeted therapy is highly effective in BRAF V600E (50% of melanomas) but resistance develops in most; tumour-infiltrating lymphocyte (TIL) therapy (Amtagvi, 2024) approved — cell manufacturing is complex
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Melanoma” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."